What is Apriori Bio?
Headquartered in Boston, Massachusetts, Apriori Bio operates at the intersection of immunology and computational biology. The company was established by Flagship Pioneering to address the critical gap in vaccine efficacy caused by viral mutation. By utilizing a sophisticated technology platform, Apriori Bio surveys the entire spectrum of existing and potential viral variants, enabling the design of vaccines that offer durable, broad-spectrum protection. This proactive approach to pandemic preparedness positions the firm as a vital player in global health security, moving beyond traditional reactive vaccine development models to anticipate future pathogen trajectories.
How much funding has Apriori Bio raised?
Apriori Bio has raised a total of $1.1M across 1 funding round:
Other Financing Round
$1.1M
Other Financing Round (2024): $1.1M with participation from Cepi Centre Enseignement Publications Informatiques
Key Investors in Apriori Bio
Cepi Centre Enseignement Publications Informatiques
A French-based organization operating within the publishing sector, providing strategic support to innovative ventures.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Apriori Bio?
The recent infusion of capital is expected to accelerate the clinical development of Apriori Bio's lead candidates and expand its computational infrastructure. As the company transitions into a more mature operational phase, the focus will likely shift toward scaling its platform capabilities and forging strategic partnerships with international health organizations. By maintaining its commitment to variant-resilient protection, Apriori Bio is well-positioned to navigate the complexities of the evolving viral landscape, potentially setting a new standard for how the industry approaches long-term immunity and pandemic resilience.
See full Apriori Bio company page
